{"entity":{"id":"steven-treon","kind":"person","name":"Steven P. Treon","aka":[],"tldr":"Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug.","summary":"Steven Treon led the whole-genome sequencing that found the MYD88 L265P mutation in more than 90% of Waldenström macroglobulinaemia, a diagnostic marker and therapeutic target, and then the pivotal trial of ibrutinib that produced the disease's first FDA approval. He identified CXCR4 mutations as a resistance mechanism and directs the world's largest Waldenström research centre at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom"}],"tags":["lymphoma","waldenstrom","genomics"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":["kinase-inhibitors","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Waldenström macroglobulinaemia","MYD88 and CXCR4 genomics","BTK inhibitors","Rare lymphomas"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom"}],"papers":[{"title":"MYD88 L265P somatic mutation in Waldenström's macroglobulinemia","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1200710"},{"title":"Ibrutinib in previously treated Waldenström's macroglobulinemia","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1501548"}],"orcid":"0000-0001-6393-6154"},"route":"/people/steven-treon/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}]}}